Investment Considerations for Pharmaceutical Product Portfolios

Raymond A. Huml ()
Additional contact information
Raymond A. Huml: Quintiles Transnational Corp.

Chapter Chapter 4 in Optimization of Pharmaceutical R&D Programs and Portfolios, 2015, pp 49-69 from Springer

Abstract: Abstract Pharmaceutical executives with varying backgrounds and expertise are increasingly being asked to provide input on complex strategies related to portfolios of products, including regulatory and commercial competitive intelligence. Given the appropriate expertise – including preclinical, clinical pharmacology, clinical, regulatory affairs, CMC (Chemistry, Manufacturing and Controls)/supply chain, commercial, and patent law – they may be asked to help estimate the probabilities of achieving clinical milestones such as regulatory approval in a market of interest. They may also be asked to comment on product development even earlier in the development cycle, taking into account commercial insights, payer perspectives and quality-of-life issues. This chapter discusses investment decisions based on the author’s experience in investing in portfolios of pharmaceutical products, such as how much one can invest, and the palatability of the proposed return structure. The chapter breaks down many facets of this complex process to give insights into business decisions related to portfolios. Differences in portfolio strategy between big pharma and biotech companies are discussed, along with portfolio management, innovative partnering strategies and commercial perspectives

Keywords: Competitive intelligence; Due diligence; Clinical development milestones; Investment return structures; Pharmaceutical product portfolio strategy; Partnering (search for similar items in EconPapers)
Date: 2015
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-319-09075-7_4

Ordering information: This item can be ordered from
http://www.springer.com/9783319090757

DOI: 10.1007/978-3-319-09075-7_4

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().